Market research
RHO6.F Roche Holding AG
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 315B
- P/E ratio
- 24.14
- Analyst target
- 52.44
- Dividend yield
- 20.%
- Beta
- 0.35
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- US7711951043
- Market cap
- 315B
- P/E ratio
- 24.14
- Analyst target
- 52.44
- Dividend yield
- 20.%
- Beta
- 0.35
About
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RHO6.F discussion.
5 years, 4 months ago
Roche Holding AG is currently in a long term uptrend where the price is trading 12.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Finally, its free cash flow fell by 32.8% to $5B since the same quarter in the previous year.
Based on the above factors, Roche Holding AG gets an overall score of 2/5.